Quantcast

Latest Oncolytics Biotech Inc. Stories

2014-09-03 16:29:18

In the news release, Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study, issued 03-Sep-2014 by Oncolytics Biotech Inc. over CNW, we are advised by the company that at the end of the fourth paragraph, "150 patients" should read "110 patients". The complete, corrected release follows: Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study CALGARY,...

2014-09-03 08:32:29

CALGARY, Sept. 3, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN(®) versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study chair is David E. Cohn, MD, gynecologic oncology division director at The Ohio State University Comprehensive Cancer Center -...

2014-09-02 08:28:45

CALGARY, Sept. 2, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Baird 2014 Health Care Conference in a session on Wednesday September 3(rd), 2014 at 9:05 a.m. ET. The conference takes place on September 3(rd) and 4(th) at the New York Palace, in New York, NY. A live audio link to the webcast session will be available at: http://wsw.com/webcast/baird39/oncy or on the company's website at...

2014-07-08 08:29:42

CALGARY, July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN(®) versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The principal investigator is Tanios Bekaii-Saab, MD, associate professor and gastrointestinal oncology section...

2014-06-19 08:28:06

CALGARY, June 19, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated May 9, 2014 were elected as directors at its 2014 Annual Meeting of Shareholders, held on Wednesday June 18(th), 2014. On a vote by ballot, the following 10 nominees proposed by management were elected as Directors of Oncolytics to serve until the Company`s next Annual Meeting of Shareholders or until their...

2014-06-16 08:27:41

CALGARY, June 16, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2014 Annual Meeting of Shareholders will be held on Wednesday June 18(th), 2014 at 4:30pm ET at the TMX Broadcast Centre, 130 King Street West, Toronto, ON Following the business portion of the meeting, Dr. Brad Thompson, President and CEO of Oncolytics, will discuss recent progress in the development of REOLYSIN(®) as a potential cancer therapeutic. A live audio...

2014-06-02 08:29:05

CALGARY, June 2, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Jefferies 2014 Global Healthcare Conference in a session on Tuesday June 3(rd), 2014 at 4:00 p.m. ET. The conference takes place from June 2(nd) to 5(th) in New York, NY. A live audio link to the webcast session will be available at: http://wsw.com/webcast/jeff82/ONCY or on the company's website at...

2014-05-21 20:22:00

CALGARY, May 21, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced the nomination of Ms. Linda Hohol and Ms. Angela Holtham to its slate of directors for election by shareholders at its upcoming Annual General Meeting to be held June 18, 2014 in Toronto, Ontario, Canada. The Company today also announced that Fred Stewart, QC will not be standing for re-election at this year's meeting. "Fred Stewart has been an...

2014-05-20 08:31:42

CALGARY, May 20, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN(®) to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website at http://abstracts.asco.org. The conference is being held from May 30(th) to June 3(rd), 2014 in Chicago, Illinois. "Treatment...

2014-05-08 08:31:49

CALGARY, May 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the first quarter ended March 31, 2014. "During the quarter we reported additional data from our head and neck study which will help us with the design of our proposed registration study for discussion with regulators," said Dr. Brad Thompson, President and CEO of Oncolytics. "We also took steps to...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.